计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L125568-5mg |
5mg |
现货 ![]() |
| |
| L125568-10mg |
10mg |
现货 ![]() |
| |
| L125568-50mg |
50mg |
现货 ![]() |
|
| 别名 | 拉罗皮兰 |
|---|---|
| 英文别名 | Laropiprant [USAN:INN:BAN] | 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid | (-)-((3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic acid | L |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Laropiprant |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 拮抗剂 |
| 作用机制 | 类固醇 DP 受体拮抗剂 |
| 产品介绍 |
Laropiprant(MK 0524)是高活性DP1受体拮抗剂,Ki为 0.57 nM,对DP2受体的Ki为750nM。 Laropiprant(MK 0524) is a potent, selective DP1 receptor antagonist with Ki value of 0.57 nM; exhibits >1,000 fold selectivity over DP2 receptor (Ki=0.75 uM). |
| ALogP | 3.5 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IUPAC Name | 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid |
| INCHI | InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1 |
| InChi Key | NXFFJDQHYLNEJK-CYBMUJFWSA-N |
| Canonical SMILES | CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CCC3CC(=O)O)CC4=CC=C(C=C4)Cl)F |
| Isomeric SMILES | CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F |
| PubChem CID | 9867642 |
| 分子量 | 435.9 |
| 溶解性 | DMSO |
|---|---|
| 分子量 | 435.900 g/mol |
| XLogP3 | 3.500 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 435.071 Da |
| 单同位素质量Monoisotopic Mass | 435.071 Da |
| 拓扑极表面积Topological Polar Surface Area | 84.800 Ų |
| 重原子数Heavy Atom Count | 29 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 721.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(HPLC) | 98-100(%) |
|---|---|
| Appearance(L125568) | White to off-white solid |
| NMR spectrum | Conforms to Structure |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 23-05-10 | L125568 |
| 1. Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N et al.. (2007) Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).. J Med Chem, 50 (4): (794-806). [PMID:17300164] |
| 2. Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E et al.. (2006) Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.. Proc Natl Acad Sci USA, 103 (17): (6682-7). [PMID:16617107] |
| 3. Lai E, Wenning LA, Crumley TM, De Lepeleire I, Liu F, de Hoon JN, Van Hecken A, Depré M, Hilliard D, Greenberg H et al.. (2008) Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.. Clin Pharmacol Ther, 83 (6): (840-7). [PMID:17882161] |